AngioDynamics Inc. (NASDAQ: ANGO) reported a web loss for the second quarter of 2025 because the medical gadget firm’s revenues decreased 8%.
Web loss, excluding particular objects, was $0.04 per share within the November quarter, in comparison with a lack of $0.05 per share within the corresponding interval of 2024. On an unadjusted foundation, web loss narrowed to $10.7 million or $0.26 per share in Q2 from $29 million or $0.72 per share within the prior-year quarter.
Revenues, on a reported foundation, decreased 8% year-over-year to $72.8 million within the second quarter. The corporate continues to count on fiscal 2025 gross sales within the vary of $282 million to $288 million.
Commenting on the outcomes, AngioDynamics’ CEO Jim Clemmer mentioned, “We’re very enthusiastic about our sturdy efficiency in the course of the second quarter, and specifically the continued energy of our Med Tech phase,
which grew 25% over the prior 12 months.”
